Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Published:2021-05 Issue:10286 Volume:397 Page:1736-1748
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Enebo Lone B,Berthelsen Kasper K,Kankam Martin,Lund Michael T,Rubino Domenica M,Satylganova Altynai,Lau David C W

Funder

Novo Nordisk AS

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Health effects of overweight and obesity in 195 countries over 25 years;Afshin;N Engl J Med,2017

2. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis;Guh;BMC Public Health,2009

3. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes;Wing;Diabetes Care,2011

4. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors' expert forum;Cefalu;Diabetes Care,2015

5. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity;Garvey;Endocr Pract,2016

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity;Current Diabetes Reviews;2024-10

2. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis;Indian Journal of Endocrinology and Metabolism;2024-09-04

3. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

4. Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?;Digestive and Liver Disease;2024-09

5. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review;eClinicalMedicine;2024-09